CONMED Corp (CNMD) · Oct 28, 2026 · Earnings

CONMED earnings beat on EPS as sales outlook narrows

Beat — Adjusted EPS $1.04 vs ~$1.00 consensus

CONMED earnings beat on adjusted EPS and delivered sharp margin expansion, but revenue missed slightly and full-year organic growth guidance narrowed.

CONMED is in the middle of a portfolio reset: it is exiting gastroenterology products and concentrating resources on minimally invasive surgery, smoke evacuation, and orthopedic soft-tissue repair, led by AirSeal, Buffalo Filter, and BioBrace.

The quarter beat on the metric that matters most for earnings. Adjusted diluted EPS was $1.04 versus a published consensus of approximately $1.00, while revenue of $335.6 million was slightly below the roughly $336.3 million expectation. Management explicitly said adjusted EPS exceeded expectations. 〔0〕

MetricQ3 2026Q3 2025 / prior guidanceRead
Revenue$335.6M$337.9MDown 0.7% reported (Consolidated Condensed Statements of Income)
Organic constant-currency sales growth6.7%—Strong underlying growth despite GI exits (Sales Summary)
Adjusted diluted EPS$1.04$1.08Above ~$1.00 consensus; below prior-year adjusted EPS (Reconciliation of Reported Net Income to Adjusted Net Income)
Adjusted EBITDA margin20.2%19.4%Up 80 basis points (Reconciliation of Net Income to EBITDA & Adjusted EBITDA)
FY2026 adjusted EPS guidance$4.54–$4.61$4.48–$4.60Raised at both ends (Updated Financial Guidance)
FY2026 organic constant-currency sales growth5.0%–5.5%5.0%–6.0%High end reduced (Updated Financial Guidance)

Underlying demand was much better than reported revenue suggests. Total sales declined 0.7% because the company is removing exited GI products from its portfolio, but organic constant-currency growth reached 6.7% in the quarter. Orthopedic Surgery grew 12.7% organically in constant currency and General Surgery grew 12.6%, showing that the focused portfolio is gaining traction rather than simply shrinking. (Sales Summary — Three Months Ended September 30, 2026)

Profitability was the strongest part of the release. Reported operating margin rose to 11.1% from 3.5%, while adjusted EBITDA margin improved to 20.2% from 19.4%. That expansion reflects better operating leverage and a cleaner portfolio, although the quarter still included $3.2 million of operational optimization costs and $1.9 million tied to European medical-device regulations. (Consolidated Condensed Statements of Income; Reconciliation of Net Income to EBITDA & Adjusted EBITDA)

The guidance change is favorable on earnings but less encouraging on growth. CONMED raised the full-year adjusted EPS range from $4.48–$4.60 to $4.54–$4.61, but narrowed the organic constant-currency sales outlook from 5.0%–6.0% to 5.0%–5.5%. The company is converting solid underlying demand into better earnings, but the top-line ceiling is lower than it previously expected. 〔1〕

Bottom line: This was a narrow earnings beat built on margin improvement and healthy growth in the prioritized businesses, not a clean revenue win. The portfolio reset is working operationally, but the reduced sales-growth ceiling keeps the overall read from being decisively strong.

Original filing on SEC EDGAR

CONMED earnings beat on EPS as sales outlook narrows | CNMD Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.